The U.K.'s National Institute for Health and Clinical Excellence is reviewing a proposal that would limit coverage by the National Health Service of costly medicines for inflammatory bowel diseases, restricting use to patients whose condition worsens. Patients said preventing them from getting such drugs regularly would put them in a lifetime of pain. The National Association for Colitis and Crohn's Disease and other groups also oppose the proposal.

Related Summaries